The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Drugging the ‘undruggable’ cancer targets
Open accessAbstract
The term 'undruggable' was coined to describe proteins that could not be targeted pharmacologically. However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'. Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacologically targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies. In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Transcription factors have remained challenging drug targets due to the absence of druggable active sites (14).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Self-citationPeptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,160
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Self-citationDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Flagged first, then by citations
Cited by
Sorted by citations
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Wang, Y., Zhang, S., Li, F., Zhou, Y., Zhang, Y., Wang, Z., Zhang, R., Zhu, J., Ren, Y., Tan, Y. C., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz981 · Cited by 798
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652
Integrative Proteomic Characterization of Human Lung Adenocarcinoma
Xu, J., Zhang, C., Wang, X., Zhai, L., Ma, Y., Mao, Y., Qian, K., Sun, C., Liu, Z., Jiang, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.043 · Cited by 617
Small molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 637
Targeting RNA structures with small molecules
Childs‐Disney, J. L., Yang, X., Gibaut, Q. M. R., Tong, Y., Batey, R., & Disney, M. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00521-4 · Cited by 636
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537
Overcoming Endosomal Entrapment in Drug Delivery
Pei, D., & Buyanova, M. Y. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00778 · Cited by 418
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 404
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles
Luther, D. C., Huang, R., Jeon, T., Zhang, X., Lee, Y.-W., Nagaraj, H., & Rotello, V. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.020 · Cited by 380
MYC protein interactors in gene transcription and cancer
Lourenco, C., Resetca, D., Redel, C., Lin, P., MacDonald, A. S., Ciaccio, R., Kenney, T. M. G., Wei, Y., Andrews, D. W., Sunnerhagen, M., et al. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00367-9 · Cited by 351
Novel therapeutic strategies: targeting epithelial–mesenchymal transition in colorectal cancer
Zhang, N., Ng, A. S., Cai, S., Li, Q., Li, Y., & Kerr, D. J. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00343-0 · Cited by 364
Wheatley, S., & Altieri, D. (2019) · Journal of Cell Science · doi:10.1242/jcs.223826 · Cited by 328
DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges
Gironda-Martínez, A., Donckele, E. J., Samain, F., & Neri, D. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00118 · Cited by 344
Biomolecular Condensates and Cancer
Boija, A., Klein, I. A., & Young, R. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.003 · Cited by 338
SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315
Empowering biomedical discovery with AI agents
Gao, S., Fang, A., Huang, Y., Giunchiglia, V., Noori, A., Schwarz, J. R., Ektefaie, Y., Kondic, J., & Zitnik, M. (2024) · Cell · doi:10.1016/j.cell.2024.09.022 · Cited by 315
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E. (2019) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 300
Trends in the approval of cancer therapies by the FDA in the twenty-first century
Scott, E., Baines, A. C., Gong, Y. U. T., Moore, R. V., Pamuk, G. E., Saber, H., Subedee, A., Thompson, M. D., Xiao, W., Pazdur, R., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00723-4 · Cited by 291
The current understanding of KRAS protein structure and dynamics
Pantsar, T. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.12.004 · Cited by 304
Targeted protein degradation: A promise for undruggable proteins
Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 297
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 295
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 274
Zeng, S., Huang, W., Zheng, X., Cheng, L., Zhang, Z., Wang, J., & Shen, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112981 · Cited by 264
The MYC oncogene is a global regulator of the immune response
Casey, S. C., Baylot, V., & Felsher, D. W. (2018) · Blood · doi:10.1182/blood-2017-11-742577 · Cited by 257
Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
Łukasik, P., Załuski, M., & Gutowska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062935 · Cited by 262
Targeting EMT in Cancer with Repurposed Metabolic Inhibitors
Ramesh, V., Brabletz, T., & Ceppi, P. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.06.005 · Cited by 245
Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
Bemis, T. A., Clair, J. J. L., & Burkart, M. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00482 · Cited by 250
Zhang, L., Yao, Y., Zhang, S., Liu, Y., Guo, H., Ahmed, M., Bell, T., Zhang, H., Han, G., Lorence, E., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau1167 · Cited by 233
IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling
Sheng, X., Nenseth, H. Z., Qu, S., Kuzu, O. F., Frahnow, T., Simon, L. M., Greene, S., Zeng, Q., Fazli, L., Rennie, P. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08152-3 · Cited by 235
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
Peptide–nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms?
Jeong, W.-J., Bu, J., Kubiatowicz, L. J., Chen, S. S., Kim, Y. S., & Hong, S. (2018) · Nano Convergence · doi:10.1186/s40580-018-0170-1 · Cited by 230
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Nada, H., Choi, Y., Kim, S.-D., Jeong, K. S., Meanwell, N. A., & Lee, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02036-3 · Cited by 241
Jeong, W.-J., Ro, E. J., & Choi, K.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0049-y · Cited by 220
Targeted Intracellular Delivery of Antibodies: The State of the Art
Slastnikova, T. A., Ulasov, A. V., Rosenkranz, A. A., & Sobolev, A. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01208 · Cited by 214
An omics perspective on drug target discovery platforms
Paananen, J., & Fortino, V. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz122 · Cited by 216
Application of Fragment-Based Drug Discovery to Versatile Targets
Li, Q. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00180 · Cited by 212
Polyamines: Functions, Metabolism, and Role in Human Disease Management
Sagar, N. A., Tarafdar, S., Agarwal, S., Tarafdar, A., & Sharma, S. (2021) · Medical Sciences · doi:10.3390/medsci9020044 · Cited by 210
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
Garralda, E., Beaulieu, M.-È., Moreno, V., Casacuberta‐Serra, S., Martínez-Martín, S., Foradada, L., Alonso, G., Massó-Vallés, D., López‐Estévez, S., Jauset, T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02805-1 · Cited by 219
Self-citationPrey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004310 · Cited by 201
PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
Tinworth, C. P., Lithgow, H., Dittus, L., Bassi, Z. I., Hughes, S. E., Muelbaier, M., Dai, H., Smith, I. E. D., Kerr, W. J., Burley, G. A., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01094 · Cited by 195
Recent Advances in Oligonucleotide Therapeutics in Oncology
Xiong, H., Veedu, R. N., & Diermeier, S. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073295 · Cited by 194
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G. H., Azam, S. H., Ozkan‐Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.001 · Cited by 187
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101974 · Cited by 185
Pioneer of prostate cancer: past, present and the future of FOXA1
Teng, M., Zhou, S., Cai, C., Lupien, M., & He, H. H. (2020) · Protein & Cell · doi:10.1007/s13238-020-00786-8 · Cited by 180
Allosteric Modulator Discovery: From Serendipity to Structure-Based Design
Lu, S., He, X., Ni, D., & Zhang, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01749 · Cited by 179
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C., & Voisin‐Chiret, A. S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103395 · Cited by 180
Reimagining Druggability Using Chemoproteomic Platforms
Spradlin, J. N., Zhang, E., & Nomura, D. K. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00065 · Cited by 176
Current and Future Treatment Strategies for Rhabdomyosarcoma
Chen, C. Y., García, H. D., Scheer, M., & Henssen, A. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01458 · Cited by 180
Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex
Calabrese, D. R., Chen, X., Leon, E. C., Gaikwad, S. M., Phyo, Z., Hewitt, W. M., Alden, S., Hilimire, T. A., He, F., Michalowski, A. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06315-w · Cited by 172
Current Advances in Aptamers for Cancer Diagnosis and Therapy
Hori, S.-I., Herrera, A., Rossi, J. P., & Zhou, J. (2018) · Cancers · doi:10.3390/cancers10010009 · Cited by 171
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy
Bonazzi, S., d’Hennezel, E., Beckwith, R. E. J., Xu, L., Fazal, A., Magracheva, A., Ramesh, R., Cernijenko, A., Antonakos, B., Bhang, H.-E. C., et al. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.02.005 · Cited by 167
How We Think about Targeting RNA with Small Molecules
Costales, M. G., Childs‐Disney, J. L., Haniff, H. S., & Disney, M. D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01927 · Cited by 164
Small molecule recognition of disease-relevant RNA structures
Meyer, S. M., Williams, C. C., Akahori, Y., Tanaka, T., Aikawa, H., Tong, Y., Childs‐Disney, J. L., & Disney, M. D. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00560f · Cited by 159
Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC
Boike, L., Cioffi, A. G., Majewski, F. C., Co, J., Henning, N. J., Jones, M. D., Liu, G., McKenna, J. M., Tallarico, J. A., Schirle, M., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.09.001 · Cited by 154
Creating and screening natural product libraries
Wilson, B. A. P., Thornburg, C. C., Henrich, C. J., Grkovic, T., & O’Keefe, B. R. (2020) · Natural Product Reports · doi:10.1039/c9np00068b · Cited by 164
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159
Is β-Catenin a Druggable Target for Cancer Therapy?
Cui, C., Zhou, X., Zhang, W., Qu, Y., & Ke, X. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.06.003 · Cited by 168
Identifying strategies to target the metabolic flexibility of tumours
Méndez‐Lucas, A., Lin, W., Driscoll, P. C., Legrave, N. M., Novellasdemunt, L., Xie, C., Charles, M. D., Wilson, Z., Jones, N. P., Rayport, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0195-8 · Cited by 148
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
Massó-Vallés, D., & Soucek, L. (2020) · Cells · doi:10.3390/cells9040883 · Cited by 146
Self-citationLi, X., Zhang, Z., Gao, F., Ma, Y., Wei, D., Lu, Z., Chen, S., Wang, M., Wang, Y., Xu, K., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c02619 · Cited by 145
CDK12: an emerging therapeutic target for cancer
Lui, G. Y. L., Grandori, C., & Kemp, C. J. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205356 · Cited by 132
Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors
Anderson, G. R., Wardell, S. E., Çakır, M., Yip, C., Ahn, Y.-R., Ali, M., Yllanes, A. P., Chao, C., McDonnell, D. P., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-04033-x · Cited by 137
Targeting intrinsically disordered proteins at the edge of chaos
Ruan, H., Sun, Q., Zhang, W., Liu, Y., & Lai, L. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.017 · Cited by 133
Fragment-based covalent ligand discovery
Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136
The state of the art of PROTAC technologies for drug discovery
Wang, C., Zheng, C., Wang, H., Zhang, L., Liu, Z., & Xu, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114290 · Cited by 129
Structure-based drug design: aiming for a perfect fit
van Montfort, R. L. M., & Workman, P. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170052 · Cited by 127
Current therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115
Novel Computational Approach to Predict Off-Target Interactions for Small Molecules
Rao, M. S., Gupta, R., Liguori, M. J., Hu, M., Huang, X., Mantena, S. R., Mittelstadt, S. W., Blomme, E. A. G., & Vleet, T. R. V. (2019) · Frontiers in Big Data · doi:10.3389/fdata.2019.00025 · Cited by 125
Zhang, P., Park, H.-J., Zhang, J., Junn, E., Andrews, R. J., Velagapudi, S. P., Abegg, D., Vishnu, K., Costales, M. G., Childs‐Disney, J. L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905057117 · Cited by 125
Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.023 · Cited by 125
A bibliometric analysis of PROTAC from 2001 to 2021
Li, D., Yu, D., Li, Y., & Yang, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114838 · Cited by 125
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 122
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 124
Agoni, C., Olotu, F. A., Ramharack, P., & Soliman, M. E. S. (2020) · Journal of Molecular Modeling · doi:10.1007/s00894-020-04385-6 · Cited by 117
Integrated proteogenomic characterization of urothelial carcinoma of the bladder
Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01291-7 · Cited by 115
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy
Zhao, R., Fu, J., Zhu, L., Chen, Y., & Liu, B. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01230-6 · Cited by 109
Annual review of PROTAC degraders as anticancer agents in 2022
Wang, X., Qin, Z.-L., Li, N., Jia, M.-Q., Liu, Q.-G., Bai, Y., Song, J., Yuan, S., & Zhang, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116166 · Cited by 107
Xia, Y., Ye, B., Ding, J., Yu, Y., Alptekin, A., Thangaraju, M., Prasad, P. D., Ding, Z., Park, E. J., Choi, J.-H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3541 · Cited by 108
Aptamer-Based Targeted Protein Degradation
Liu, Y., Qian, X., Ran, C., Li, L., Fu, T., Su, D., Xie, S., & Tan, W. (2023) · ACS Nano · doi:10.1021/acsnano.2c10379 · Cited by 110
Wang, K., Elsayed, M., Wu, G., Deng, N., Cushman, M., & Yang, D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02679 · Cited by 106
Targeting the undruggables—the power of protein degraders
Zhang, C., Liu, Y., Li, G., Yang, Z., Han, C., Sun, X., Sheng, C., Ding, K., & Rao, Y. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.03.056 · Cited by 112
MYC in cancer: from undruggable target to clinical trials
Whitfield, J. R., & Soucek, L. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01143-2 · Cited by 106
Self-citationAccelerating Drug Discovery: Synthesis of Complex Chemotypes via Multicomponent Reactions
Buskes, M. J., Coffin, A. R., Troast, D. M., Stein, R., & Blanco, M.-J. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00012 · Cited by 103
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
Papatzimas, J. W., Gorobets, E., Maity, R., Muniyat, M. I., MacCallum, J. L., Neri, P., Bahlis, N. J., & Derksen, D. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00455 · Cited by 103
Recent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 117
Current Insights of BRAF Inhibitors in Cancer
Agianian, B., & Gavathiotis, E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01306 · Cited by 103
Aberrant phase separation and cancer
Taniue, K., & Akimitsu, N. (2021) · FEBS Journal · doi:10.1111/febs.15765 · Cited by 101
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Antibody Delivery for Intracellular Targets: Emergent Therapeutic Potential
Singh, K., Ejaz, W., Dutta, K., & Thayumanavan, S. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00025 · Cited by 104
The long journey to bring a Myc inhibitor to the clinic
Whitfield, J. R., & Soucek, L. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202103090 · Cited by 101
Self-citationStrategies for targeting undruggable targets
Zhang, G., Zhang, J., Gao, Y., Li, Y., & Li, Y. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1969359 · Cited by 104
Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins
Lin, J., Jin, J., Shen, Y., Zhang, L., Gong, G., Bian, H., Chen, H., Nagle, D. G., Wu, Y., Zhang, W., et al. (2021) · Theranostics · doi:10.7150/thno.62686 · Cited by 102
Evaluation of 3-Dimensionality in Approved and Experimental Drug Space
Prosser, K. E., Stokes, R. W., & Cohen, S. M. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00121 · Cited by 98
The multidimensional role of the Wnt/β‐catenin signaling pathway in human malignancies
Hiremath, I. S., Goel, A., Warrier, S. R., Kumar, A. P., Sethi, G., & Garg, M. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30561 · Cited by 101
Jeon, S., Jeon, Y., Lim, J.-Y., Kim, Y., Cha, B., & Kim, W. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02070-1 · Cited by 105
Metadata
- Authors
- Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L.
- Affiliations
- The Wistar Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Howard Hughes Medical Institute (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Dang, Chi V.
- Reddy, E. Premkumar
- Shokat, Kevan M.
- Soucek, Laura
- Venue
- Nature Reviews Cancer
- Published
- 2017-06-23
- Volume
- 17
- Issue
- 8
- Pages
- 502-508
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC5945194
- OpenAlex
- W2692768525
- Cited by
- 927
- References
- 57
- Citations by year
- 2026: 93 · 2025: 113 · 2024: 125 · 2023: 110 · 2022: 121 · 2021: 121 · 2020: 113 · 2019: 63 · 2018: 58 · 2017: 10
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (R01CA057341, R01CA158209, R01CA051497)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- oncogenic Ras, MYC oncogene, oncogene targeting, anticancer drug development
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Receptors, Androgen, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-myc, NF-kappa B, ras Proteins, Proto-Oncogene Proteins c-myb, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
